Odyssey Therapeutics Reports Positive Phase 2a Results for OD-001
Odyssey Therapeutics announces encouraging Phase 2a trial results for OD-001, enhancing its standing in the biological products industry.
Flutter Entertainment announces restructuring plan, cuts jobs
Flutter Entertainment plc plans to restructure its UK and Ireland operations, potentially cutting 1,400 jobs due to rising gaming taxes.
United Community Banks reports strong Q3 results, growth
United Community Banks, Inc. announces robust Q3 earnings, highlighting strategic initiatives and significant growth in loans and deposits.
Kroger unveils multi-year growth strategy and targets
Kroger Co. announces a new growth strategy aimed at enhancing customer experience and financial performance through 2029.
Hertz forms joint venture with investors, reshaping strategy
Hertz Global Holdings announces a joint venture with key investors, marking a strategic shift in its operations and impacting the auto rental industry.
Iridium Communications Reports Strong Q3 Results, Acquisition Update
Iridium Communications Inc. announces strong Q3 2026 results and updates on its acquisition by Rocket Lab, signaling growth in the communications industry.
Western Alliance Bancorporation Reports Strong Q3 2026 Results
Western Alliance Bancorporation announces strong financial results for Q3 2026, showcasing growth in net income and earnings per share.
Halliburton reports third quarter results for 2026
Halliburton Company announces its financial results for Q3 2026, showcasing key performance metrics and insights into the oil and gas field services industry.
MSCI Reports Strong Q3 2026 Financial Results
MSCI Inc. announces significant revenue growth and profitability for Q3 2026, reflecting its strong position in the business services industry.
CRISPR Therapeutics appoints Andrew J. Silver as CFO
CRISPR Therapeutics AG has appointed Andrew J. Silver as its new Chief Financial Officer, effective immediately, strengthening its financial leadership.
3M Company updates Q3 results and full-year guidance
3M Company reports third-quarter financial results and updates its full-year guidance, reflecting ongoing strategic adjustments in the medical instruments sector.
Quoin Pharmaceuticals Publishes Study on QRX003 for Netherton Syndrome
Quoin Pharmaceuticals announces publication of peer-reviewed study on QRX003, a therapy for Netherton Syndrome, showcasing significant patient improvements.
Equifax reports 10% revenue growth for Q3 2026 results
Equifax Inc. announces a 10% revenue growth for Q3 2026, driven by strong performance in diversified markets, returning $158 million to shareholders.
KeyCorp Reports Strong Q3 2026 Results with $537 Million Net Income
KeyCorp announces a robust Q3 2026 with $537 million net income, showcasing strong performance in the national commercial banking sector.
General Electric reports strong Q3 2026 earnings results
General Electric Co. announces substantial growth in Q3 2026 earnings, raising full-year guidance amid a competitive landscape in the electrical equipment industry.
Hasbro reports strong Q3 results, raises outlook and buyback
Hasbro Inc. announces a 15% revenue increase in Q3, raising its financial outlook and doubling its share repurchase target amid strong demand for its products.
W. R. Berkley Corporation Reports Third-Quarter Results
W. R. Berkley Corporation announces strong third-quarter results, highlighting its performance in the fire, marine, and casualty insurance sector.
Brand Engagement Network Inc. Announces Cost Reductions Post-Acquisition
Brand Engagement Network Inc. outlines expected cost reductions following its acquisition of Cataneo GmbH, aiming for annualized savings of $1.919 million.
Chubb Ltd reports strong Q3 2026 results with income growth
Chubb Ltd's Q3 2026 results show increased net income and premiums, indicating strong performance in the fire, marine, and casualty insurance industry.
Rapport Therapeutics announces positive Phase 2 trial results
Rapport Therapeutics reports positive results from its Phase 2 trial of RAP-219 for bipolar mania, paving the way for Phase 3 trials in 2027.